GBS detection with molecular biology-based method – Bogiel et al.
June, 2021Increased sensitivity for S.agalactiae detection vs culture techniques
Read Now 2 minsIncreased sensitivity for S.agalactiae detection vs culture techniques
Read Now 2 minsDiscover and dowload this infographics for COVID-19 and Flu symptoms.
Read Now 1 minPublication from Camargo et al. comparing diagnostic methods
Read Now 2 minsVan der Pol et al. study on clinical results for various sample types
Read Now 2 minsProspective study of PCR testing impact on SSI rate by Tansarli et al.
Read Now 2 minsEvaluation of rectal swabs on the BD MAX™ Check-Points CPO assay
Read Now 2 minsResults revealed an NPA above 99.4% for all targets - Stoke et al.
Read Now 2 minsStudy from Simner et al. across six clinical sites
Read Now 2 mins100% sensitivity for Cryptosporidium spp. and G.duodenalis
Read Now 2 mins
Connect with professionals from around the world BD MAX™ Club members represent a community of professionals in infectious diseases and molecular diagnostics. With regional meet-ups and live webinars from global experts, expand your laboratory’s network and collaborate with worldwide colleagues.
Tailored medical and technical expertise Whether you need compelling scientific research or tutorials for troubleshooting on the BD MAX™ System, BD MAX™ Club is here to accompany your molecular diagnostics journey. Log in to your BD MAX™ Club account anywhere, anytime to access our information database.
Exclusive members’ perks BD MAX™ Club membership unlocks doors to exclusive webinars and collaboration with industry leading experts. Engage with your colleagues in the molecular community and exchange with the BD research and development team.
The information included on this website and other information provided from time to time through webcasts, conference calls, securities analyst meetings, road show presentations, investor conferences, newsletters and similar events and communications contains forward-looking statements (as defined under Federal securities laws) based on current expectations and assumptions that involve risks and uncertainties. If the risks or uncertainties ever materialize or the assumptions prove incorrect, the results of BD may differ materially from those expressed or implied by such forward-looking statements and assumptions. Forward-looking statements may be identified by the use of words such as “plan,” “expect,” “believe,” “intend,” “will,” “may,” “anticipate,” “estimate” and other words of similar meaning in conjunction with, among other things, discussions of future operations and financial performance (including volume growth, pricing, sales and earnings per share growth, and cash flows) and statements regarding our strategy for growth, future product development, regulatory approvals, competitive position and expenditures.
All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. Many of these risks and uncertainties are beyond the company’s control. For a discussion of certain factors that could cause our actual results to differ from our expectations in any forward-looking statements see our latest Annual Report on Form 10-K and other filings with the SEC. BD expressly disclaims any undertaking to update or revise any forward looking statements set forth herein to reflect events or circumstances after the date hereof, except as required by applicable law or regulation.